Skip to main content

BLTE Belite Bio, Inc

Healthcare

154.49

Close 10/9

Open
152.73
High
155.99
Low
152.17
Prev close
152.52
Volume
158.4K
52W 77.64 200.00
Loading candles…

Is Belite Bio, Inc a buy? Fundamentals and valuation first

As of 2026-10-09

Momentum: Strong.

Quality Neutral ROE, TTM is Average.
ROE, TTM (%) -13.18 28th percentile Average
Operating margin, TTM (%) — N/A
FCF margin, TTM (%) — N/A
Momentum Strong 240-day return is Top; 60-day return is Good.
60-day return (%) 2.54 71th percentile Good
240-day return (%) 66.44 91th percentile Top
Risk / liquidity Neutral 20-day dollar volume is Good, but 60-day annualized volatility is Average.
20-day dollar volume 23,865,541 73th percentile Good
60-day annualized volatility (%) 50.18 55th percentile Average

Belite Bio, Inc (BLTE) peers and tracking

Watchlist

This page refreshes daily after the close. Add Belite Bio, Inc to your watchlist to track signal changes on your next visit.

Belite Bio, Inc (BLTE) quant signal backtests

Market-wide momentum baseline

Across 98,394 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.23%, a 57.8% positive-return rate, and +2.88 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

More history: Signals not active now

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

11 times historically; 60-day forward avg +16.98%, win rate 70%, beating the market by +9.99 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

11 times historically; 60-day forward avg +12.71%, win rate 72.7%, beating the market by +6.71 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

Continue researching Belite Bio, Inc with the evidence above.

Continue in Studio ↗

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.
  • This is an American depositary receipt (ADR). The data does not say how many ordinary shares each ADR represents, so per-share and market-value metrics (P/E, price/book, free-cash-flow yield, EPS growth and earnings surprises) are not computed.
  • ADRs listed on NYSE or NASDAQ are covered as a separate group selected by dollar volume, in addition to the common-stock universe; the 6-month momentum signal ranks each ADR against the liquid US common stocks.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.